Methods and compositions for the reduction of neutrophil influx and the treatment of bronchopulmonary displasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease

Abstract

The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of Respiratory Distress Syndrome (RDS), Bronchopulmonary dysplasia (BPD), chronic lung disease and/or pulmonary fibrosis, Asthma and Chronic Obstructive Pulmonary Disease (COPD). More particularly, the invention provides methods, including broadly the critical dosage ranges of rhCC10, which may be administered to safely and effectively treat the aforementioned conditions. The invention further provides a composition useful in administering rhCC10 to humans.

1 . A method of treatment of a patient having respiratory distress syndrome, bronchopulmonary dysplasia, chronic lung disease, pulmonary fibrosis, asthma or chronic obstructive pulmonary disease and in need of treatment, comprising: administering a treatment-effective amount of rhCC10 to said patient. 
     
     
         2 - 37 . (canceled)